Lon­za un­veils two sep­a­rate vac­cine, ADC man­u­fac­tur­ing deals that could lead to 415 new Swiss jobs

Ahead of its Cap­i­tal Mar­kets Day on Tues­day, Lon­za an­nounced back-to-back part­ner­ship deals that cov­er two Swiss fa­cil­i­ty cus­tomiza­tions and the po­ten­tial cre­ation of around 415 new jobs once man­u­fac­tur­ing is at its peak.

On Mon­day, Lon­za and vac­cine biotech Vax­cyte said they are start­ing a new man­u­fac­tur­ing deal to sup­port the pro­duc­tion of Vax­cyte’s pneu­mo­coc­cal con­ju­gate vac­cines. In a Fri­day an­nounce­ment, the Swiss com­pa­ny al­so said it has ex­pand­ed its col­lab­o­ra­tion with an un­named “ma­jor bio­phar­ma­ceu­ti­cal part­ner” to meet its bio­con­ju­gate han­dling and fill­ing needs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER